Cardinal Health Inc. (CAH) - NYSE
  • Sun, Jul. 3, 2:50 PM
    • via Barclays:
    • "Although stocks in the U.S. and Europe have partially bounced back from the sharp selloff sparked by the U.K. referendum result, risks remain prevalent. [Analyst] Keith Parker foresees further equity downside alongside a prolonged market bottoming process, during which positioning is likely to turn much more defensive at active managers.
    • "With this in mind, our stock screen this week highlights Overweight-rated stocks that screen defensively based on sector and equity beta but are also expected to generate superior ROE and free cash flows in FY1.
    • "Our screen considers the following factors: i) Large-cap (US $5 billion+) stock in the consumer staples, utilities, telecom or healthcare sectors. ii) Adjusted beta less than 1.0. iii) Rated Overweight by Barclays equity research. iv) 15%+ ROE and 4.5%+ FCF yield expected in FY1, based on Barclays estimates."
    • The stocks: Aetna (NYSE:AET), BT Group plc (NYSE:BT), Cardinal Health (NYSE:CAH), Coloplast (OTC:CLPBF, OTCPK:CLPBY), CVS (NYSE:CVS), Estee Lauder (NYSE:EL), Express Scripts (NASDAQ:ESRX), Glanbia (OTC:GLAPF, OTCPK:GLAPY), Grifols (NASDAQ:GRFS), Imperial Brands (OTCQX:IMBBY, OTCQX:ITYBF), Johnson & Johnson (NYSE:JNJ), Ahold (OTCQX:AHONY, OTCQX:AHODF, OTCQX:AHOND), LabCorp (NYSE:LH), Perrigo (NYSE:PRGO), Telus (NYSE:TU), Unilever (UL, UN), UnitedHealth Group (NYSE:UNH)
    • See full table here.
    | Sun, Jul. 3, 2:50 PM | 14 Comments
  • Mon, Jun. 27, 11:50 AM
    • Thinly traded nano cap Akers Biosciences (AKER +33.9%) is up on a whopping 109x surge in volume (1.9M shares) in response to its announcement that Cardinal Health (CAH -1.8%) unit Aero-Med will distribute its BreathScan OxiChek, a disposable breath test to rapidly determine levels of oxidative stress in the body, an indicator of overall health in a person.
    • Aero-Med has already placed orders for the product. It intends to focus its direct sales efforts on areas with high numbers of anti-aging, functional and integrative health and wellness treatment centers. It will initially target six New England states. Financial terms are not disclosed.
    • Akers intends to engage additional distributors for other markets, including chiropractors and multi-level marketing organizations.
    | Mon, Jun. 27, 11:50 AM | 4 Comments
  • Mon, May 23, 12:39 PM
    • "Politics is now a topic in every client discussion," say David Kostin and team, and the nature of today's electorate nearly assures a close race, even though prediction markets currently assign a high probability of a Clinton victory.
    • When uncertainty rises, consumer staples (NYSEARCA:XLP) typically outperforms, while tech (NYSEARCA:XLK) lags.
    • Getting down to names, with protectionism and tax policy two key areas of debate, buy those stocks with high U.S. sales and high effective tax rates, and avoid those with high foreign sales and low tax rates.
    • High U.S. sales and high tax rates (buy): Cardinal Health (NYSE:CAH), Fidelity National (NYSE:FIS), Discover (NYSE:DFS), AmerisourceBergen (NYSE:ABC), Schwab (NYSE:SCHW), ADP (NASDAQ:ADP), Chipotle (NYSE:CMG), Reynolds America (NYSE:RAI), Express Scripts (NASDAQ:ESRX), Alliance Data (NYSE:ADS), Fiserv (NASDAQ:FISV), Paychex (NASDAQ:PAYX), Whole Foods (NASDAQ:WFM), Akamai (NASDAQ:AKAM), Intuit (NASDAQ:INTU), Southwest Airlines (NYSE:LUV).
    • High foreign sales and low tax rates (avoid): Abbott Labs (NYSE:ABT), Agilent (NYSE:A), Mondelez (NASDAQ:MDLZ), XL Group (NYSE:XL), Waters (NYSE:WAT), Priceline (NASDAQ:PCLN), Transocean (NYSE:RIG), PerkinElmer (NYSE:PKI), Nvidia (NASDAQ:NVDA), Lam Research (NASDAQ:LRCX), Western Digital (NASDAQ:WDC).
    | Mon, May 23, 12:39 PM | 18 Comments
  • Sun, May 8, 5:07 PM
    • Cardinal Health (NYSE:CAH) declares $0.4489/share quarterly dividend, 16% increase from prior dividend of $0.387.
    • Forward yield 2.34%
    • Payable July 15; for shareholders of record July 1; ex-div June 29.
    | Sun, May 8, 5:07 PM | 8 Comments
  • Thu, Apr. 28, 9:54 AM
    • Cardinal Health (CAH -5.9%) fiscal Q3 results ($M): Total Revenues: 30,662 (+20.8%); Pharmaceutical: 27,527 (+21.8%); Medical: 3,138 (+13.1%).
    • Net Income: 386 (+5.8%); Non-GAAP Net Income: 472 (+19.2%); EPS: 1.17 (+7.3%); Non-GAAP EPS: 1.43 (+20.2%); CF Ops: 919 (+39.7%).
    • 2016 Guidance: Non-GAAP EPS: $5.17 - 5.27 from $5.15 - 5.35. Consensus view is $5.28.
    | Thu, Apr. 28, 9:54 AM | 11 Comments
  • Thu, Apr. 28, 7:04 AM
    • Cardinal Health (NYSE:CAH): FQ3 EPS of $1.43 beats by $0.10.
    • Revenue of $30.66B (+20.8% Y/Y) beats by $270M.
    • Press Release
    | Thu, Apr. 28, 7:04 AM | 3 Comments
  • Wed, Apr. 27, 5:30 PM
  • Fri, Mar. 18, 12:56 PM
    • Vitae Pharmaceuticals (VTAE +8.2%) upgraded to Buy from Hold by Stifel. Price target set at $15 (105% upside).
    • Johnson & Johnson (JNJ +0.8%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $112 (4% upside) from $102.
    • HCA Holdings (HCA +2.8%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $85 (12% upside) from $76.
    • Epizyme (EPZM +9.8%) upgraded to Buy from Neutral by H.C. Wainwright. Price target raised to $25 (127% upside) from $22.
    • Agenus (AGEN +2.7%) upgraded to Buy from Hold with a $7 (81% upside) price target by Maxim Group.
    • Juno Therapeutics (JUNO +2.6%) upgraded to 4.5 stars (out of a possible 5.0) by the Vetr Community. The implied price target is $45.47 (17% upside).
    • Alnylam Pharmaceuticals (ALNY +3.2%) upgraded to Overweight from Neutral by JP Morgan. Price target lowered to $81 (37% upside) from $111.
    • Amicus Therapeutics (FOLD +4.3%) upgraded to Buy from Neutral by Janney Capital. Price target raised to $12 (59% upside) from $10.
    • Pernix Therapeutics Holdings (PTX -5%) downgraded to Market Perform from Outperform by Oppenheimer. $9 price target removed.
    • Valeant Pharmaceuticals (VRX -6.6%) downgraded to Neutral from Buy by Nomura. Price target lowered to $60 (116% upside) from $175. Morgan Stanley maintains Equal Weight rating but lowers price target to $39 (40% upside) from $98. Stifel rates it a Buy but lowered its price target to $65 (134% upside) from $200. Rodman & Renshaw rates it a Buy with a $118 (324% upside) price target (from $150). Piper Jaffray downgraded it to Underweight from Neutral with no price target.
    • AstraZeneca (AZN -1.5%) downgraded to Hold from Buy by Jefferies. Price target lowered to 4,350p (12% upside) from 4,900p.
    • Cardinal Health (CAH +1.4%) and McKesson (MCK +4.4%) both downgraded to Market Perform from Outperform by Cowen & Company. Price targets lowered to $90 (11% upside) and $173 (9% upside), respectively.
    | Fri, Mar. 18, 12:56 PM | 26 Comments
  • Tue, Feb. 2, 4:22 PM
    • Cardinal Health (NYSE:CAH) declares $0.387/share quarterly dividend, in line with previous.
    • Forward yield 1.99%
    • Payable April 15; for shareholders of record April 1; ex-div March 30.
    | Tue, Feb. 2, 4:22 PM
  • Mon, Feb. 1, 7:02 AM
    • Cardinal Health (NYSE:CAH): FQ2 EPS of $1.30 beats by $0.04.
    • Revenue of $31.45B (+23.1% Y/Y) beats by $2.22B.
    | Mon, Feb. 1, 7:02 AM | 1 Comment
  • Sun, Jan. 31, 5:30 PM
    | Sun, Jan. 31, 5:30 PM | 1 Comment
  • Tue, Jan. 12, 9:51 AM
    • Ahead of this morning's presentation at the J.P. Morgan Healthcare Conference in San Francisco, Cardinal Health (CAH +1.7%) affirms its non-GAAP EPS guidance for fiscal 2016 of $5.15 - 5.35, representing an increase of 18 to 22%. Fiscal Q2 results should be released by the end of the month.
    | Tue, Jan. 12, 9:51 AM | 2 Comments
  • Dec. 8, 2015, 3:18 PM
    • It's been a rough run for value stocks over the past few years, but the metric used to determine value - price/book - may not be the right one, says Citi's Robert Buckland. Free-cash-flow yield is better, he argues. noting this metric tracked traditional value in the 1990s and 2000s, but has easily outperformed over the past decade.
    • It's a sign of the times, he says, as FCF is a "capex-suspicious metric," and investors are concerned about the economic outlook, and cynical about capital allocation decisions of managements.
    • The list of 28 U.S. value (as defined by FCF yield) plays: BHI, VIAB, WFM, ANTM, HPQ, ABC, LBTYA, M, AAPL, CTL, XRX, LYB, CMI, ETN, MRK, VLO, CSCO, WRK, IBM, LVS, ESRX, IP, CAH, ADM, INTC, CAT, ABBV, EMN
    | Dec. 8, 2015, 3:18 PM | 49 Comments
  • Nov. 4, 2015, 5:46 PM
    • Cardinal Health (NYSE:CAH) declares $0.387/share quarterly dividend, in line with previous.
    • Forward yield 1.79%
    • Payable Jan. 15; for shareholders of record Jan. 4; ex-div Dec. 30.
    | Nov. 4, 2015, 5:46 PM
  • Nov. 2, 2015, 9:14 AM
    | Nov. 2, 2015, 9:14 AM
  • Nov. 2, 2015, 7:02 AM
    • Cardinal Health (NYSE:CAH): FQ1 EPS of $1.38 beats by $0.28.
    • Revenue of $28.1B (+16.7% Y/Y) beats by $920M.
    | Nov. 2, 2015, 7:02 AM | 3 Comments
Company Description
Cardinal Health, Inc. is a healthcare services company providing pharmaceutical and medical products and services that help pharmacies, hospitals, surgery centers, physician offices and other healthcare providers focus on patient care while reducing costs, enhancing efficiency and improving... More
Sector: Services
Industry: Drugs Wholesale
Country: United States